<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491006</url>
  </required_header>
  <id_info>
    <org_study_id>ATH-1017-AD-0202</org_study_id>
    <secondary_id>U1111-1255-9714</secondary_id>
    <secondary_id>18PTC-R-589358</secondary_id>
    <secondary_id>1R01AG068268-01</secondary_id>
    <nct_id>NCT04491006</nct_id>
  </id_info>
  <brief_title>A Translational Study of ATH-1017 in Mild to Moderate Alzheimer's Disease</brief_title>
  <acronym>ACT-AD</acronym>
  <official_title>A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athira Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Athira Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate treatment effects of fosgonimeton (ATH-1017) in mild to&#xD;
      moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to assess the correlation of the functional translational biomarker&#xD;
      P300 latency and change in ADAS-Cog11 induced by ATH-1017 therapy, over 26-week randomized,&#xD;
      double-blind treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Actual">May 20, 2022</completion_date>
  <primary_completion_date type="Actual">May 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, parallel-group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Related Potential</measure>
    <time_frame>Week 26</time_frame>
    <description>Event-related potential (ERP) P300 latency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>Weeks 2, 6, 12, 20, and 26</time_frame>
    <description>Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog11] (Range of 0 to 70, where 0 is least impairment and 70 is most severe impairment)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia of Alzheimer Type</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily subcutaneous (SC) injection of Low Dose ATH-1017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily subcutaneous (SC) injection of High Dose ATH-1017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily subcutaneous (SC) injection of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATH-1017</intervention_name>
    <description>Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age 55 to 85 years&#xD;
&#xD;
          -  Mild-to-moderate AD dementia subjects, MMSE 14-24, CDR 1 or 2 at Screening&#xD;
&#xD;
          -  Clinical diagnosis of dementia, due probably to AD, by Revised National Institute on&#xD;
             Aging-Alzheimer's Association criteria (McKhann, 2011)&#xD;
&#xD;
          -  Reliable and capable support person/caregiver&#xD;
&#xD;
          -  Treatment-free or receiving stable acetylcholinesterase inhibitor (AChEI) treatment,&#xD;
             defined as:&#xD;
&#xD;
               -  Treatment-na√Øve, OR&#xD;
&#xD;
               -  Subjects are on a stable, approved dose of an AChEI (except for donepezil at 23&#xD;
                  mg PO) for at least 3 months before Screening OR&#xD;
&#xD;
               -  Subjects who received an AChEI in the past and discontinued 4 weeks prior to&#xD;
                  Screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of significant neurologic disease, other than AD, that may affect cognition,&#xD;
             or concurrent with the onset of dementia&#xD;
&#xD;
          -  History of unexplained loss of consciousness, and epileptic fits (unless febrile)&#xD;
&#xD;
          -  Subject has atypical variant presentation of AD, if known from medical history,&#xD;
             particularly non-amnestic AD&#xD;
&#xD;
          -  History of brain MRI scan indicative of any other significant abnormality&#xD;
&#xD;
          -  Hearing test result considered unacceptable for auditory ERP P300 assessment&#xD;
&#xD;
          -  Diagnosis of severe major depressive disorder even without psychotic features&#xD;
&#xD;
          -  Significant suicide risk&#xD;
&#xD;
          -  History within 2 years of Screening, or current diagnosis of psychosis&#xD;
&#xD;
          -  Myocardial infarction or unstable angina within the last 6 months&#xD;
&#xD;
          -  Clinically significant (in the judgment of the investigator) cardiac arrhythmia&#xD;
             (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (note:&#xD;
             pacemaker is acceptable)&#xD;
&#xD;
          -  Subject has either hypertension (supine diastolic blood pressure &gt; 95 mmHg), or&#xD;
             symptomatic hypotension in the judgment of the investigator&#xD;
&#xD;
          -  Clinically significant ECG abnormality at Screening&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine &gt; 2.0 mg/dL)&#xD;
&#xD;
          -  Hepatic impairment with alanine aminotransferase or aspartate aminotransferase &gt; 2&#xD;
             times the upper limit of normal, or Child-Pugh class B and C&#xD;
&#xD;
          -  Malignant tumor within 3 years before Screening&#xD;
&#xD;
          -  Memantine in any form, combination or dosage within 4 weeks prior to Screening&#xD;
&#xD;
          -  Donepezil at 23 mg PO&#xD;
&#xD;
          -  The subject has received active amyloid or tau immunization (i.e., vaccination for&#xD;
             Alzheimer's disease) at any time, or passive immunization (i.e., monoclonal antibodies&#xD;
             for Alzheimer's disease) within 6 months of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cognitive Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Health Research Program</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Neurosciences Research</name>
      <address>
        <city>Central Coast</city>
        <state>New South Wales</state>
        <zip>2261</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Centre for Applied Medical Research, Translational Research Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammondcare Greenwich Hospital</name>
      <address>
        <city>Greenwich</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KaRa MINDS</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2113</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HammondCare</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Alzheimer's Research Organization</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.</citation>
    <PMID>21514250</PMID>
  </reference>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>July 5, 2022</last_update_submitted>
  <last_update_submitted_qc>July 5, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Cognition</keyword>
  <keyword>Dementia</keyword>
  <keyword>ATH-1017</keyword>
  <keyword>Memory Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

